185 related articles for article (PubMed ID: 25480501)
1. Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.
Ariës IM; van den Dungen RE; Koudijs MJ; Cuppen E; Voest E; Molenaar JJ; Caron HN; Pieters R; den Boer ML
Haematologica; 2015 Apr; 100(4):e132-6. PubMed ID: 25480501
[No Abstract] [Full Text] [Related]
2. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
Oshima K; Khiabanian H; da Silva-Almeida AC; Tzoneva G; Abate F; Ambesi-Impiombato A; Sanchez-Martin M; Carpenter Z; Penson A; Perez-Garcia A; Eckert C; Nicolas C; Balbin M; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Devidas M; Loh ML; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando AA
Proc Natl Acad Sci U S A; 2016 Oct; 113(40):11306-11311. PubMed ID: 27655895
[TBL] [Abstract][Full Text] [Related]
3. The NR4A orphan nuclear receptors do not confer prednisolone resistance in pediatric acute lymphoblastic leukemia.
Ariës IM; van den Dungen ES; Pieters R; den Boer ML
Leukemia; 2014 Feb; 28(2):422-5. PubMed ID: 24056879
[No Abstract] [Full Text] [Related]
4. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
Perentesis JP; Bhatia S; Boyle E; Shao Y; Shu XO; Steinbuch M; Sather HN; Gaynon P; Kiffmeyer W; Envall-Fox J; Robison LL
Leukemia; 2004 Apr; 18(4):685-92. PubMed ID: 14990973
[TBL] [Abstract][Full Text] [Related]
5. RAS and FMS mutations following cytotoxic therapy for childhood acute lymphoblastic leukaemia.
Taylor C; McGlynn H; Carter G; Baker AH; Warren N; Ridge SA; Owen G; Thompson E; Thompson PW; Jacobs A
Leukemia; 1995 Mar; 9(3):466-70. PubMed ID: 7885045
[TBL] [Abstract][Full Text] [Related]
6. Profiling gene mutations, translocations, and multidrug resistance in pediatric acute lymphoblastic leukemia: a step forward to personalizing medicine.
Rose-James A; Shiji R; Kusumakumary P; Nair M; George SK; Sreelekha TT
Med Oncol; 2016 Sep; 33(9):98. PubMed ID: 27449773
[TBL] [Abstract][Full Text] [Related]
7. [Results and suggestion from comparing between world excellent protocols of childhood acute lymphoblastic leukemia].
Fu RY; Liao QK; Jia CS
Zhonghua Er Ke Za Zhi; 2003 Jul; 41(7):515-9. PubMed ID: 14746678
[No Abstract] [Full Text] [Related]
8. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
[TBL] [Abstract][Full Text] [Related]
9. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
10. Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia.
Janiszewska H; Styczynski J; Kolodziej B; Wysocki M; Haus O
Ann Hematol; 2009 Dec; 88(12):1193-8. PubMed ID: 19352661
[TBL] [Abstract][Full Text] [Related]
11. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.
Hulleman E; Kazemier KM; Holleman A; VanderWeele DJ; Rudin CM; Broekhuis MJ; Evans WE; Pieters R; Den Boer ML
Blood; 2009 Feb; 113(9):2014-21. PubMed ID: 18978206
[TBL] [Abstract][Full Text] [Related]
13. Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.
Spenerova M; Dzubak P; Srovnal J; Radova L; Burianova R; Konecny P; Salkova S; Novak Z; Pospisilova D; Stary J; Blazek B; Hak J; Votava T; Timr P; Kaiserova E; Bubanska E; Mihal V; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):422-7. PubMed ID: 23128824
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia.
Choonara I; Wheeldon J; Rayner P; Blackburn M; Lewis I
Cancer Chemother Pharmacol; 1989; 23(6):392-4. PubMed ID: 2713960
[TBL] [Abstract][Full Text] [Related]
15. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Ramakers-van Woerden NL; Pieters R; Hoelzer D; Slater RM; den Boer ML; Loonen AH; Harbott J; Janka-Schaub GE; Ludwig WD; Ossenkoppele GJ; van Wering ER; Veerman AJ;
Med Pediatr Oncol; 2002 Jun; 38(6):379-86. PubMed ID: 11984797
[TBL] [Abstract][Full Text] [Related]
16. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
17. Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia.
Tissing WJ; Lauten M; Meijerink JP; den Boer ML; Koper JW; Sonneveld P; Pieters R
Haematologica; 2005 Sep; 90(9):1279-81. PubMed ID: 16154856
[TBL] [Abstract][Full Text] [Related]
18. [Re-induction therapy of relapsed Ph(+) acute lymphoblastic leukemia with T315I mutation by HA regimen in combination with HD-MTX regimen].
Li Z; Zhao Y; Qi XF
Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):54. PubMed ID: 23597466
[No Abstract] [Full Text] [Related]
19. Acute lymphoblastic leukaemia presenting as breast mass.
Jain AK; Gupta RC; Bhardwaj B; Leelani N
J Assoc Physicians India; 1992 May; 40(5):335-6. PubMed ID: 1483996
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.
Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB
Oncotarget; 2016 Sep; 7(37):58728-42. PubMed ID: 27623214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
